The closed-loop neurostimulation market is estimated at USD 1.2 billion in 2025 and is projected to reach USD 6.0 billion by 2035, expanding at a CAGR of 17.5% during the forecast period 2026–2035.

ARTARMON, Australia, Jan. 21, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that data from multiple studies evaluating the company's Evoke ® ECAP-Controlled, ...

World's First Commercial Implants of the Evoke System Completed in The Netherlands ­­­­ARTARMON, Australia, Sept. 16, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced ...

Evoke is a novel, closed-loop SCS system that instantaneously reads, records, and responds to evoked compound action potentials. The Food and Drug Administration (FDA) has approved the Evoke ® Spinal ...

There’s another company poised to make an impact on the way chronic pain is treated in the U.S. Artarmon, Australia-based Saluda Medical has just won FDA approval for the Evoke Spinal Cord Stimulation ...

BLOOMINGTON, Minn., July 16, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX: SLD, "Saluda" or the "Company"), a commercial‑stage medical device company advancing closed‑loop neuromodulation for ...

BLOOMINGTON, Minn., June 30, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX: SLD, "Saluda" or the "Company"), a commercial-stage medical device company focused on developing treatments for chronic ...

The UK's Newcastle Hospitals National Health Service (NHS) Foundation Trust has fitted a teenage patient with a spinal cord stimulator (SCS) implant, making the patient the first adolescent in the UK, ...

Medtronic plc is looking to increase market share in pain stimulation with its differential target multiplexed (DTM) therapy, a recharge-free device and its next big disrupter, evoked compound action ...